Curated News
By: NewsRamp Editorial Staff
March 06, 2026
VolitionRx Automates Pet Cancer Testing in Japan with Fujifilm Partnership
TLDR
- VolitionRx's automated cancer test for pets in Japan provides a market advantage with faster processing for over 1,700 veterinary hospitals.
- VolitionRx validated its Nu.Q Vet Cancer Test with Fujifilm Vet Systems for automated processing on the IDS i10 analyzer platform in Japan.
- Automated pet cancer testing in Japan enables earlier detection for millions of dogs, improving animal health outcomes and quality of life.
- VolitionRx's automated pet cancer test in Japan uses the same platform as human tests, creating cross-species diagnostic synergy.
Impact - Why it Matters
This development represents a significant advancement in veterinary medicine that directly impacts pet owners and the animal healthcare industry. For the millions of pet owners in Japan and potentially worldwide, automated cancer testing means faster, more reliable results for their beloved animals, potentially leading to earlier interventions and better outcomes. The automation of the Nu.Q Vet Cancer Test addresses a critical need in veterinary diagnostics where timely results can be life-saving. This innovation also demonstrates how medical technology developed for humans can be successfully adapted for veterinary use, creating synergies that benefit both fields. As pet healthcare becomes increasingly sophisticated and pet owners seek human-grade medical care for their animals, such advancements in diagnostic technology help bridge the gap between human and veterinary medicine, potentially extending and improving the quality of life for companion animals while supporting the growing demand for advanced veterinary services.
Summary
VolitionRx (NYSE American: VNRX) has achieved a significant milestone in veterinary cancer diagnostics through its partnership with Fujifilm Vet Systems Co. Ltd in Japan. The company announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test, enabling full automation on the IDS i10 automated analyzer platform. This transition from manual plates to automated processing is expected to support faster turnaround times and higher throughput as demand grows, with more than 1,700 veterinary hospitals in Japan already registered to use the test. Volition highlighted Japan's approximately seven million pet dogs and noted the automated platform aligns with the same system used for its human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy and the company's commitment to advancing epigenetics science.
Volition is a multi-national company focused on developing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with additional facilities in the U.S. and London. This development represents a crucial step in Volition's mission to save lives and improve outcomes for both people and animals through earlier detection and monitoring of life-altering diseases. The company's website provides further information about their innovative approach to disease detection and monitoring.
The news was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio that provides advanced wire-grade press release syndication for private and public companies. InvestorWire offers comprehensive distribution solutions including article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution through IBN, and tailored corporate communications solutions. This platform helps companies like Volition reach a wide audience of investors, influencers, consumers, journalists and the general public, ensuring maximum impact for their announcements in today's information-saturated market.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Automates Pet Cancer Testing in Japan with Fujifilm Partnership
